Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The prognostic significance of microsatellites in cutaneous melanoma.

Niebling MG, Haydu LE, Lo SN, Rawson RV, Lamboo LGE, Stollman JT, Karim RZ, Thompson JF, Scolyer RA.

Mod Pathol. 2020 Feb 13. doi: 10.1038/s41379-020-0500-9. [Epub ahead of print]

PMID:
32055007
2.

Melanoma pathology reporting and staging.

Scolyer RA, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VG.

Mod Pathol. 2020 Jan;33(Suppl 1):15-24. doi: 10.1038/s41379-019-0402-x. Epub 2019 Nov 22. Review.

PMID:
31758078
3.

Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy.

Jackett LA, Colebatch AJ, Rawson RV, Ferguson PM, Thompson JF, McCarthy SW, Wilmott JS, Scolyer RA.

Am J Surg Pathol. 2020 Mar;44(3):357-367. doi: 10.1097/PAS.0000000000001406.

PMID:
31743128
4.

From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years.

Rawson RV, Scolyer RA.

Hum Pathol. 2019 Nov 6. pii: S0046-8177(19)30196-0. doi: 10.1016/j.humpath.2019.09.017. [Epub ahead of print]

PMID:
31704364
5.

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, J├Ânsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA.

Nat Commun. 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107-x.

6.

Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management.

Rawson RV, Bailey T, Colebatch AJ, Ferguson P.

Melanoma Manag. 2019 Jun 14;6(1):MMT18. doi: 10.2217/mmt-2019-0002. No abstract available.

7.

Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication.

Scolyer RA, Soyer HP, Kelly JW, James C, McLean CA, Coventry BJ, Ferguson PM, Rawson RV, Mar VJ, de Menezes SL, Fishburn P, Stretch JR, Lee S, Thompson JF.

Aust J Gen Pract. 2019 Jun;48(6):357-362. doi: 10.31128/AJGP-11-18-4759.

8.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3.

PMID:
31171444
9.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.

Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Oncotarget. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29.

10.

A teenager with a black nodule on the buttock.

Wong XL, Rawson RV, Sebaratnam DF.

J Paediatr Child Health. 2019 Feb;55(2):240. doi: 10.1111/jpc.1_14302. No abstract available.

PMID:
30746881
11.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

12.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

13.

Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma.

Rawson RV, Watson GF, Maher AM, McCarthy SW, Thompson JF, Scolyer RA.

Pathology. 2017 Aug;49(5):539-542. doi: 10.1016/j.pathol.2017.03.005. Epub 2017 Jul 8. No abstract available.

PMID:
28693747
14.

Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas.

Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV.

Eur J Cancer. 2017 Sep;82:167-170. doi: 10.1016/j.ejca.2017.05.042. Epub 2017 Jul 6. No abstract available.

PMID:
28689094
15.

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS.

Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9.

16.

1-Triiodothyronine versus 1-throxine; a comparison of their metabolic effects in human myxedema.

RAWSON RV, RALL JE, PEARSON OH, ROBBINS J, POPPELL HF, WEST CD.

Am J Med Sci. 1953 Oct;226(4):405-11. No abstract available.

PMID:
13092101

Supplemental Content

Loading ...
Support Center